PriceTargets.com logo

Curis - CRIS Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $9.50
  • Forecasted Upside: 1,148.69%
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$0.76 As of 02/6/2023 01:00 AM ET
▼ -0.02 (-2.56%)

This chart shows the closing price for CRIS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Curis Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CRIS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CRIS

Analyst Price Target is $9.50
▲ +1,148.69% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Curis in the last 3 months. The average price target is $9.50, with a high forecast of $15.00 and a low forecast of $4.00. The average price target represents a 1,148.69% upside from the last price of $0.76.

This chart shows the closing price for CRIS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 investment analysts is to buy stock in Curis. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/16/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/14/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
2/12/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
5/13/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
8/11/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/9/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/8/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
2/7/2023

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/10/2022HC WainwrightLower TargetBuy$16.00 ➝ $9.00Low
9/21/2022Cantor FitzgeraldReiterated RatingOverweightLow
4/5/2022Cantor FitzgeraldLower Target$12.00 ➝ $4.00High
4/5/2022B. RileyLower TargetBuy$22.00 ➝ $10.00High
4/4/2022Raymond JamesDowngradeOutperform ➝ Market Perform$15.00High
4/1/2022Cantor FitzgeraldReiterated RatingOverweightN/A
3/2/2022Cantor FitzgeraldLower Target$24.00 ➝ $12.00High
10/13/2021Raymond JamesInitiated CoverageOutperform$15.00High
8/4/2021B. RileyReiterated RatingBuy$22.00Medium
6/14/2021HC WainwrightReiterated RatingBuy$20.00High
6/14/2021B. RileyReiterated RatingBuy$22.00Medium
5/13/2021B. RileyBoost TargetPositive ➝ Buy$19.00 ➝ $22.00High
5/13/2021Cantor FitzgeraldBoost TargetOverweight$15.00 ➝ $24.00High
3/24/2021B. RileyInitiated CoverageBuy$19.00High
3/17/2021JonestradingBoost TargetBuy$14.00 ➝ $18.00High
1/15/2021HC WainwrightBoost TargetBuy$9.00 ➝ $16.00N/A
12/16/2020Cantor FitzgeraldBoost TargetPositive ➝ Overweight$4.00 ➝ $15.00Low
12/8/2020HC WainwrightBoost TargetBuy$5.00 ➝ $9.00N/A
11/24/2020HC WainwrightInitiated CoverageBuy$5.00Medium
7/29/2020LaidlawInitiated CoverageBuy$5.00Medium
7/16/2020Cantor FitzgeraldInitiated CoverageOverweight$4.00 ➝ $4.00High
9/25/2018CowenReiterated RatingBuyMedium
8/6/2018CowenReiterated RatingBuyMedium
8/3/2018SunTrust BanksLower TargetBuy$8.00High
5/7/2018Robert W. BairdLower TargetOutperform ➝ Outperform$30.00Low
(Data available from 2/7/2018 forward)

News Sentiment Rating

-0.15 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/12/2022
  • 3 very positive mentions
  • 11 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/11/2022
  • 2 very positive mentions
  • 14 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
9/10/2022
  • 1 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
10/10/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
11/9/2022
  • 0 very positive mentions
  • 3 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
12/9/2022
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/8/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
2/7/2023

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

  • No very positive mentions tracked during this time.
Curis logo
Curis, Inc. engages in the development and commercialization of drug candidates for the treatment of human cancers. Its pipeline includes CUDC-907, CA-4948, CA-170 and CA-327. The CUDC-907 pipeline is an orally available small molecule inhibitor of HDAC and PI3K enzymes. The CA-170 pipeline is an also an orally-available small molecule antagonist of PD-L1 and VISTA immune checkpoints. The company was founded on February 14, 2000 and is headquartered in Lexington, MA.
Read More

Today's Range

Now: $0.76
Low: $0.75
High: $0.78

50 Day Range

MA: $0.66
Low: $0.47
High: $0.81

52 Week Range

Now: $0.76
Low: $0.47
High: $3.76

Volume

369,779 shs

Average Volume

681,029 shs

Market Capitalization

$73.34 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.89

Frequently Asked Questions

What sell-side analysts currently cover shares of Curis?

The following Wall Street analysts have issued reports on Curis in the last twelve months: B. Riley, Cantor Fitzgerald, HC Wainwright, Raymond James, and StockNews.com.
View the latest analyst ratings for CRIS.

What is the current price target for Curis?

4 Wall Street analysts have set twelve-month price targets for Curis in the last year. Their average twelve-month price target is $9.50, suggesting a possible upside of 1,148.7%. Raymond James has the highest price target set, predicting CRIS will reach $15.00 in the next twelve months. Cantor Fitzgerald has the lowest price target set, forecasting a price of $4.00 for Curis in the next year.
View the latest price targets for CRIS.

What is the current consensus analyst rating for Curis?

Curis currently has 1 hold rating and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CRIS will outperform the market and that investors should add to their positions of Curis.
View the latest ratings for CRIS.

What other companies compete with Curis?

Other companies that are similar to Curis include SAB Biotherapeutics, Acorda Therapeutics, Candel Therapeutics, Aptose Biosciences and Brainstorm Cell Therapeutics. Learn More about companies similar to Curis.

How do I contact Curis' investor relations team?

Curis' physical mailing address is 128 Spring Street Building C - Suite 500, LEXINGTON MA, 02421. The biotechnology company's listed phone number is (617) 503-6500 and its investor relations email address is [email protected] The official website for Curis is www.curis.com. Learn More about contacing Curis investor relations.